Actively Recruiting
Study of DM5167 in Patients With Advanced Solid Tumors
Led by DIGMBIO · Updated on 2025-08-03
58
Participants Needed
4
Research Sites
118 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.
CONDITIONS
Official Title
Study of DM5167 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 19 years or older as of the date of written informed consent
- Patients who have at least one measurable lesion according to RECIST version 1.1
- ECOG performance status 64 1
- Patients with life expectancy 65 12 weeks
- Patients who meet the clinical laboratory test criteria confirming adequate liver, renal, and hematologic function
- Patients who voluntarily provide written informed consent to participate in this study
- Patients with histologically or cytologically confirmed unresectable advanced solid tumors
- Patients who have BRCA1/BRCA2 mutations
You will not qualify if you...
- Patients with a medical history of significant illness
- Patients with QT interval of > 450 ms (for men) or > 460 ms (for women)
- Patients who have not yet recovered from toxicity related to previous anticancer therapy
- Patients predicted to demonstrate hypersensitivity to the components of the investigational medicinal product
- Patients who have participated in another clinical trial and received an investigational product or medical device
- Other individuals deemed inappropriate for participation in the study by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
Actively Recruiting
2
Samsung Medical Center
Seoul, South Korea
Actively Recruiting
3
Seoul National University Hospital
Seoul, South Korea
Actively Recruiting
4
Severance Hospital
Seoul, South Korea
Actively Recruiting
Research Team
M
MyungEun Jung
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here